ReviewInternational journal of molecular sciences2015
New Immunosuppressive Therapies in Uveitis Treatment.
Review in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 41 citations in OpenAlex.
- Hypoxia and growth factor profiling in high myopia: linking HIF-1α suppression and PDGF-BB activation to structural degeneration.Frontiers in medicine · 2025Article
- IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitis.Frontiers in immunology · 2025Article
- Bibliometric analysis of the uveitis literature and research trends over the past two decades.BMJ open ophthalmology · 2023Article
- Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases.Pharmaceutics · 2023Review
- Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation.Pharmaceutics · 2023Article
- SARS-CoV-2 vaccination and uveitis: Are they linked?Annals of medicine and surgery (2012) · 2022Review
- Sympathetic ophthalmia: A comprehensive update.Indian journal of ophthalmology · 2022Review
- Human immunocompetent choroid-on-chip: a novel tool for studying ocular effects of biological drugs.Communications biology · 2022Article
- Role of interferons in diabetic retinopathy.World journal of diabetes · 2021Review
- The Protective Effects of VVN001 on LPS-Induced Inflammatory Responses in Human RPE Cells and in a Mouse Model of EIU.Inflammation · 2021Article
- Review
- KS23, a novel peptide derived from adiponectin, inhibits retinal inflammation and downregulates the proportions of Th1 and Th17 cells during experimental autoimmune uveitis.Journal of neuroinflammation · 2019Article
- Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes.Documenta ophthalmologica. Advances in ophthalmology · 2019Article
- Update in treatment of uveitic macular edema.Drug design, development and therapy · 2019Review
- Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.Advanced healthcare materials · 2017Review
- Recent advances in managing and understanding uveitis.F1000Research · 2017Review
- Curcumin, A Potential Therapeutic Candidate for Anterior Segment Eye Diseases: A Review.Frontiers in pharmacology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveitis is an inflammatory process that initially starts in the uvea, but can also affect other adjacent eye structures, and is currently the fourth cause of blindness in developed countries. Corticoids are probably the most widespread treatment, but resorting to other immunosuppressive treatments is a frequent practice. Since the implication of different cytokines in uveitis has been well demonstrated, the majority of recent treatments for this disease include inhibitors or antibodies against these. Nevertheless, adequate treatment for each uveitis type entails a difficult therapeutic decision as no clear recommendations are found in the literature, despite the few protocolized clinical assays and many case-control studies done. This review aims to present, in order, the mechanisms and main indications of the most modern immunosuppressive drugs against cytokines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.